GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow GSK
GSK PLC Sponsored ADR (GSK) Piotroski F-score
GSK PLC Sponsored ADR's Piotroski F-score for fiscal 2025 is 9 out of 9: 9 of nine tests of profitability, leverage and efficiency passed, up from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 9 | 4.00 |
| FY2024 | 5 | 0.00 |
| FY2023 | 5 | (1.00) |
| FY2022 | 6 | 0.00 |
| FY2021 | 6 | (1.00) |
| FY2020 | 7 | 1.00 |
| FY2019 | 6 | (1.00) |
| FY2018 | 7 | 1.00 |
| FY2017 | 6 | 1.00 |
| FY2016 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 9.63% | 4.41% | Pass | 1 |
| Positive operating cash flow | 10.21b | 8.38b | Pass | 1 |
| Rising return on assets | 9.63% | 4.41% | Pass | 1 |
| Cash flow above net income | 2.67b | 5.08b | Pass | 1 |
| Falling long-term leverage | 0.25 | 0.25 | Pass | 1 |
| Rising current ratio | 0.82 | 0.78 | Pass | 1 |
| No new shares issued | 2,025,500,000 | 2,038,500,000 | Pass | 1 |
| Rising gross margin | 72.40% | 71.16% | Pass | 1 |
| Rising asset turnover | 0.55 | 0.54 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 9 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| GSK GSK PLC Sponsored ADR | 9 |
| AZN AstraZeneca PLC compare | 9 |
| NVS Novartis AG compare | 8 |
| GILD Gilead Sciences, Inc. compare | 8 |
| BMY Bristol Myers Squibb Company compare | 8 |
| SNY Sanofi compare | 7 |
| AMGN Amgen Inc. compare | 7 |
| PFE Pfizer Inc. compare | 6 |
| NVO Novo Nordisk A/S compare | 5 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover